(Reuters) - Horizon Pharma Inc (NMQ:HZNP) said it would buy Dublin-based Vidara Therapeutics International Ltd in a reverse merger for $660 million (£397.09 million), the latest U.S. company looking ...

Another day, another biopharma expansion on the Emerald Isle: Following a spate of Irish pharma growth this summer, Horizon Therapeutics is getting in on the action. Horizon has submitted a planning ...

In a bid to take advantage of low tax rates in Ireland, Horizon Pharma (NASDAQ:HZNP) unveiled plans on Wednesday to acquire Irish specialty drug maker Vidara in a $660 million cash-and-stock reverse ...

Although, there is room for more ambition, says Micol Martinelli. Ireland has achieved more than 55pc of its €1.5bn national funding target under Horizon Europe, and Marina Donohoe, the head of ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced $140,000 in scholarships to help economically disadvantaged students from Trinity College Dublin and Waterford ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been recognized as one of the Best Workplaces in Ireland 2021 by Great Place to Work Ireland, ranking No.

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: NZNP) today announced that it has been recognized as one of the 2020 Best Workplaces in Ireland, ranking 13th in the small company category.